This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Launay, E.
Right arrow Articles by Gras-Le Guen, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Launay, E.
Right arrow Articles by Gras-Le Guen, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2009, p. 1624-1627, Vol. 53, No. 4
0066-4804/09/$08.00+0     doi:10.1128/AAC.00186-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Efficacy of Ciprofloxacin in an Experimental Model of Escherichia coli Chorioamnionitis in Rabbits{triangledown}

Elise Launay,1 Nicolas Joram,1 Cédric Jacqueline,2 Anne Francoise Miegeville,2 Jocelyne Caillon,2,3 Gilles Potel,2 Jean Christophe Roze,1 and Christèle Gras-Le Guen1,2*

Département de Périnatologie, Hôpital Mère Enfant CHU Nantes, Nantes 44 093, France,1 Université de Nantes, Nantes Atlantique Universités, Thérapeutiques Cliniques et Expérimentales des Infections, EA3826, UFR Médecine, 1 Rue G. Veil, Nantes F-44035, France,2 Laboratoire de Microbiologie CHU Nantes, Nantes 44 093, France3

Received 10 February 2008/ Returned for modification 11 May 2008/ Accepted 3 December 2008

Pregnant rabbits were treated with ciprofloxacin alone or with gentamicin in a model of Escherichia coli chorioamnionitis, and the results were compared with those for untreated rabbits. The survival rate increased and the bacteremia decreased significantly in treated fetuses in comparison to controls (P = 0.003). Nevertheless, rapid selection of resistant mutants is a major limit to ciprofloxacin applications.

* Corresponding author. Mailing address: Département de Périnatologie, Hôpital Mère Enfant CHU Nantes, 38 Bd. Jean Monnet, 44093 Nantes CEDEX 1, France. Phone and fax: 33 240 083 483. E-mail: christele.grasleguen{at}chu-nantes.fr

{triangledown} Published ahead of print on 2 January 2009.

Antimicrobial Agents and Chemotherapy, April 2009, p. 1624-1627, Vol. 53, No. 4
0066-4804/09/$08.00+0     doi:10.1128/AAC.00186-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»